Nettet• MOUNTAINEER-02 is a randomized, double-blind, placebo-controlled, active comparator phase 2/3 study investigating dual HER2-inhibition of TUC and Tras with standard of … Nettet2. jul. 2024 · MOUNTAINEER is a U.S. and European multicenter, open-label, randomized phase 2 clinical trial of tucatinib in combination with trastuzumab or as a single agent …

ESMO Congress OncologyPRO

Nettet20. jan. 2024 · Of significance, the MOUNTAINEER-02 phase II/III study is ongoing (NCT04499924) and aims to evaluate the safety and efficacy of tucatinib and trastuzumab combined with ramucirumab and paclitaxel ... Nettet5. aug. 2024 · Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer … c2r tool

MOUNTAINEER-02: PHASE 2/3 STUDY OF TUCATINIB, …

Nettet• MOUNTAINEER-02 is a phase 2/3 study evaluating tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in previously-treated patients with advanced … Nettet20. jan. 2024 · Methods: MOUNTAINEER-02 (NCT04499924) is a phase 2/3 study evaluating TUC and Tras with the 2nd-line standard of care, Ram and Pac. Pts receive TUC 300 mg or placebo PO BID, Tras (6 then 4 mg/kg) or placebo (IV on Days 1 and 15 of each 28-day cycle), Pac (IV on Days 1, 8, 15), and Ram (IV on Days 1 and 15). Nettet9. jan. 2015 · This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5 … c 2s22p2